{"id":"bpi-7711","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Stomatitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BPI-7711 targets FGFR mutations and fusions that drive proliferation in certain solid tumors. By inhibiting FGFR kinase activity, the drug suppresses downstream signaling pathways critical for tumor growth and survival. This approach is particularly relevant in cancers with FGFR alterations, where the pathway is oncogenically activated.","oneSentence":"BPI-7711 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:41:52.238Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"FGFR-altered solid tumors (including cholangiocarcinoma and other FGFR-driven cancers)"}]},"trialDetails":[{"nctId":"NCT03866499","phase":"PHASE3","title":"A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beta Pharma Shanghai","startDate":"2021-04-30","conditions":"NSCLC","enrollment":369},{"nctId":"NCT03812809","phase":"PHASE2","title":"A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive","status":"COMPLETED","sponsor":"Beta Pharma Shanghai","startDate":"2019-07-05","conditions":"NSCLC","enrollment":226},{"nctId":"NCT03386955","phase":"PHASE1, PHASE2","title":"BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Beta Pharma Shanghai","startDate":"2017-08-16","conditions":"Non-small Cell Lung Cancer","enrollment":215},{"nctId":"NCT04135833","phase":"PHASE1","title":"A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711","status":"COMPLETED","sponsor":"Beta Pharma, Inc.","startDate":"2019-12-12","conditions":"NSCLC","enrollment":31},{"nctId":"NCT04135820","phase":"PHASE1","title":"A Phase I Study to Determine the Effect of Food on the Pharmacokinetic Profile of BPI-7711","status":"COMPLETED","sponsor":"Beta Pharma, Inc.","startDate":"2019-12-17","conditions":"NSCLC","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BPI-7711 capsule","BPI-7711","BPI7711 Capsule"],"phase":"phase_3","status":"active","brandName":"BPI-7711","genericName":"BPI-7711","companyName":"Beta Pharma Shanghai","companyId":"beta-pharma-shanghai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BPI-7711 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. Used for FGFR-altered solid tumors (including cholangiocarcinoma and other FGFR-driven cancers).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}